Merrimack Pharmaceuticals Inc (MACK)
15.02
+0.02
(+0.10%)
USD |
NASDAQ |
May 06, 16:00
15.02
0.00 (0.00%)
After-Hours: 16:35
Merrimack Pharmaceuticals Cash from Financing (Quarterly): 0.133M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.133M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.209M |
| March 31, 2023 | 0.179M |
| December 31, 2022 | 6.533M |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.239M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | -0.056M |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -6.638M |
| September 30, 2019 | -19.94M |
| June 30, 2019 | -15.96M |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 14.63M |
| June 30, 2018 | 0.00 |
| March 31, 2018 | |
| December 31, 2017 | -54.55M |
| Date | Value |
|---|---|
| September 30, 2017 | 1.833M |
| June 30, 2017 | -332.52M |
| March 31, 2017 | 6.077M |
| December 31, 2016 | 4.245M |
| September 30, 2016 | 1.548M |
| June 30, 2016 | 1.978M |
| March 31, 2016 | 1.645M |
| December 31, 2015 | 131.23M |
| September 30, 2015 | 41.16M |
| June 30, 2015 | 3.51M |
| March 31, 2015 | 4.265M |
| December 31, 2014 | 4.146M |
| September 30, 2014 | 2.04M |
| June 30, 2014 | 3.101M |
| March 31, 2014 | 2.134M |
| December 31, 2013 | 1.123M |
| September 30, 2013 | 147.88M |
| June 30, 2013 | 0.872M |
| March 31, 2013 | 0.411M |
| December 31, 2012 | 44.61M |
| September 30, 2012 | 0.839M |
| June 30, 2012 | 96.92M |
| March 31, 2012 | -0.07M |
| December 31, 2011 | -1.036M |
| September 30, 2011 | 0.242M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-19.94M
Minimum
Sep 2019
6.533M
Maximum
Dec 2022
-1.858M
Average
--
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | -0.026M |
| Palatin Technologies Inc | 4.974M |
| iBio Inc | 4.005M |
| Theriva Biologics Inc | -1.457M |
| Oragenics Inc | -0.1806M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.295M |
| Cash from Investing (Quarterly) | 0.068M |
| Free Cash Flow | -1.522M |
| Free Cash Flow Per Share (Quarterly) | -0.0206 |
| Free Cash Flow Yield | -0.71% |